Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Clinical trial NCT04448886 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04448886
Sponsor: Ana C Garrido-Castro, MD
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Invasive Breast Cancer Metastatic Breast Cancer HR-Positive Breast Cancer HER2-negative Breast Cancer

Start date: 2020-09-23
Primary completion: 2024-03-09
Enrollment: 110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.